Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04133675 · ClinicalTrials.gov registry record · NA
BTL Emsella Chair Versus Sham for the Treatment of Stress Urinary Incontinence
A NA study of Stress Urinary Incontinence, sponsored by Corewell Health East.
- Recruiting
- Registry status
- NA
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT04133675: Recruiting NA study of Stress Urinary Incontinence, sponsored by Corewell Health East.
NCT04133675 is a NA study of Stress Urinary Incontinence that is actively recruiting participants, run by Corewell Health East. The registered enrollment target is 110 participants, below the 160-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04133675, a NA study of Stress Urinary Incontinence, is actively recruiting participants, sponsored by Corewell Health East.
- RECRUITING
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
Stress urinary incontinence (SUI) is a condition that affects both men and women. SUI is the involuntary leakage of urine caused by an increase in intra-abdominal pressure from activities such as exercise, coughing, laughing, or sneezing. It can significantly affect quality of life as patients avoid activities or behaviors that cause leakage. This clinical trial will compare the efficacy of the Emsella chair to sham and determine if electromagnetic technology is effective in the treatment of SUI.
Primary Outcome
The primary objective of this study is to compare the efficacy of Emsella Chair to sham by evaluating the the responder rate, where a patient is called a responder if there is ≥ 50% reduction from baseline in the number stress incontinence events.
Conditions Studied
Interventions
- DEVICE BTL Emsella
- DEVICE Sham BTL Emsella
Study Locations (1)
Michigan
- Corewell Health William Beaumont University Hospital - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT04133675 shows while recruiting
NCT04133675 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 160-participant average among 35 other Stress Urinary Incontinence trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Stress Urinary Incontinence appearing as the primary indexed condition, and to 2 interventions - of which BTL Emsella is the first listed.
NCT04133675 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04133675 about?
NCT04133675 is a clinical study titled "BTL Emsella Chair Versus Sham for the Treatment of Stress Urinary Incontinence". Stress urinary incontinence (SUI) is a condition that affects both men and women. SUI is the involuntary leakage of urine caused by an increase in intra-abdominal pressure from activities such as exercise, coughing, laughing, or sneezing. It can significantly affect quality of life as patients avoid...
What is the current status of trial NCT04133675?
This trial is currently recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2019-12-18. Estimated completion is 2028-12.
What conditions does trial NCT04133675 study?
This clinical trial studies the following conditions: Stress Urinary Incontinence.
What interventions are being tested in trial NCT04133675?
The interventions under investigation include: BTL Emsella (DEVICE), Sham BTL Emsella (DEVICE).
Who is sponsoring clinical trial NCT04133675?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04133675 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04133675's enrollment target sits among peer trials
110 14th of 35 higher than 22 of 35 other Stress Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ProACT Post-Approval Study
RECRUITING · NA
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.
RECRUITING · NA
-
Impact of Unrestrictive Exercise Following Mid-Urethral Sling Surgery
RECRUITING · NA
-
Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy
RECRUITING · NA
-
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI